Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-04-20
2000-06-06
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514254, 514255, 514603, A61K 3800, A61K 31495, A61K 3150, A61K 3118
Patent
active
06071882&
ABSTRACT:
A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs Cetrorelix alone or in combination with .alpha.-reductase inhibitors or .alpha.-receptor blocking agents. The regimen reduces the volume of the prostate and avoids the side effects associated with testosterone levels being in a castration range. Cetrorelix is administered at dosages between 0.5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per day to 0.30 mg/kg body weight per week or at levels of about 25 to 120 mg of Cetrorelix per month or 0.376 mg/kg to 1.71 mg/kg per month. Cetrorelix can be administered with .alpha.-reductase inhibitors or .alpha.-receptor blocking agents.
REFERENCES:
Mori et al., Yakuri to Chiryo, 20(2), 375-81 Abstract Only, 1992.
Engel Jurgen
Rawert Jurgen
Reissmann Thomas
Riethmuller-Winzen Hilde
Asta Medica AG
Goldberg Jerome D.
LandOfFree
Means for treating prostate hypertrophy and prostate cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Means for treating prostate hypertrophy and prostate cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Means for treating prostate hypertrophy and prostate cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2213590